Medicare Coverage Policy For Alzheimer's Drugs ‘Negates’ Value Of Accelerated Approval, Lilly Says

Lilly downplays expectations for an US FDA accelerated approval of donanemab, given expectations that Medicare will persist in its plan to withhold coverage for Alzheimer's drugs outside of clinical trials. Policy experts are divided on whether the decision sets a precedent for future accelerated approvals.